Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT04902040 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04902040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04902040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
April 14, 2021
Completion date
February 27, 2025
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced bladder carcinoma, advanced lung non-small cell carcinoma, advanced malignant solid neoplasm, advanced melanoma, advanced merkel cell carcinoma, advanced renal cell carcinoma, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iii merkel cell carcinoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, clinical stage iv merkel cell carcinoma ajcc v8, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iii merkel cell carcinoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiia merkel cell carcinoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiib merkel cell carcinoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, pathologic stage iv merkel cell carcinoma ajcc v8, stage iii bladder cancer ajcc v8, stage iii lung cancer ajcc v8, stage iii renal cell cancer ajcc v8, stage iiia bladder cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib bladder cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv lung cancer ajcc v8, stage iv renal cell cancer ajcc v8, stage iva bladder cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb bladder cancer ajcc v8, stage ivb lung cancer ajcc v8